BEIJING, April 22 /PRNewswire-Asia/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC"), today reported it will exhibit at the 63rd PHARMCHINA.
Time: April 24-26, 2010
Venue: International Convention Center, Xiamen
Primary Booth: Liang Fang, Beijing Delegate Area
The Company has attended PHARMCHINA exhibitions every year since 1996 as a way to strengthen customer relationships and attract new distributors, while promoting its products.
Lotus will continue to market both its self-branded and self-produced drugs that have established market shares in China. Lotus will also introduce its upcoming innovative asthma drug Laevo-Bambutero, together with two other pipeline drugs Gliclazide-Controlled Release Tablets for type 2 diabetes and Isosorbide Mononitrate-Sustained Release Tablets for coronary artery disease.
About PHARMCHINA
PHARMCHINA has been the largest and most recognized exhibition in the Chinese pharmaceutical industry over the last thirty years. With a gross floor area of more than 60,000 square meters and leading professional and academic forums, it attracts more than 1,900 exhibitors. PHARMCHINA is a diversified trading and exchange platform for pharmaceutical companies. For more information, please see http://www.pharmchina.com.cn .
About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer of drugs and a licensed national seller of pharmaceutical items in the PRC. Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular disease, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.